Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

AMWL vs TALK vs TDOC vs OPRX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AMWL
American Well Corporation

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$129M
5Y Perf.-98.7%
TALK
Talkspace, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$868M
5Y Perf.-47.3%
TDOC
Teladoc Health, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$1.26B
5Y Perf.-96.8%
OPRX
OptimizeRx Corporation

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$124M
5Y Perf.-68.2%

AMWL vs TALK vs TDOC vs OPRX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AMWL logoAMWL
TALK logoTALK
TDOC logoTDOC
OPRX logoOPRX
IndustryMedical - Healthcare Information ServicesMedical - Care FacilitiesMedical - Healthcare Information ServicesMedical - Healthcare Information Services
Market Cap$129M$868M$1.26B$124M
Revenue (TTM)$182M$229M$2.51B$109M
Net Income (TTM)$-88M$8M$-171M$5M
Gross Margin38.7%43.0%65.6%67.3%
Operating Margin-50.6%1.4%-7.6%10.7%
Forward P/E38.2x7.0x
Total Debt$5M$0.00$1.04B$5M
Cash & Equiv.$182M$37M$781M$23M

AMWL vs TALK vs TDOC vs OPRXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AMWL
TALK
TDOC
OPRX
StockSep 20May 26Return
American Well Corpo… (AMWL)1001.3-98.7%
Talkspace, Inc. (TALK)10052.7-47.3%
Teladoc Health, Inc. (TDOC)1003.2-96.8%
OptimizeRx Corporat… (OPRX)10031.8-68.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: AMWL vs TALK vs TDOC vs OPRX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: TALK leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. OptimizeRx Corporation is the stronger pick specifically for valuation and capital efficiency and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
AMWL
American Well Corporation
The Defensive Pick

AMWL is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.47, Low D/E 1.8%, current ratio 3.37x
Best for: sleep-well-at-night
TALK
Talkspace, Inc.
The Income Pick

TALK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 0.86
  • Rev growth 22.0%, EPS growth 6.5%, 3Y rev CAGR 24.2%
  • Beta 0.86, current ratio 6.38x
  • 22.0% revenue growth vs AMWL's -2.0%
Best for: income & stability and growth exposure
TDOC
Teladoc Health, Inc.
The Secondary Option

TDOC lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
OPRX
OptimizeRx Corporation
The Long-Run Compounder

OPRX is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 110.5% 10Y total return vs TALK's -48.7%
  • Lower P/E (7.0x vs 38.2x)
  • 4.7% margin vs AMWL's -48.2%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthTALK logoTALK22.0% revenue growth vs AMWL's -2.0%
ValueOPRX logoOPRXLower P/E (7.0x vs 38.2x)
Quality / MarginsOPRX logoOPRX4.7% margin vs AMWL's -48.2%
Stability / SafetyTALK logoTALKBeta 0.86 vs OPRX's 2.28
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)TALK logoTALK+70.4% vs OPRX's -30.1%
Efficiency (ROA)TALK logoTALK5.9% ROA vs AMWL's -25.1%, ROIC 3.9% vs -95.1%

AMWL vs TALK vs TDOC vs OPRX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AMWLAmerican Well Corporation
FY 2025
Platform Subscription
53.1%$132M
Visits
37.8%$94M
Others
9.1%$23M
TALKTalkspace, Inc.

Segment breakdown not available.

TDOCTeladoc Health, Inc.
FY 2025
Other
100.0%$438M
OPRXOptimizeRx Corporation

Segment breakdown not available.

AMWL vs TALK vs TDOC vs OPRX — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTALKLAGGINGAMWL

Income & Cash Flow (Last 12 Months)

OPRX leads this category, winning 4 of 6 comparable metrics.

TDOC is the larger business by revenue, generating $2.5B annually — 23.0x OPRX's $109M. OPRX is the more profitable business, keeping 4.7% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, TALK holds the edge at +29.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAMWL logoAMWLAmerican Well Cor…TALK logoTALKTalkspace, Inc.TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…
RevenueTrailing 12 months$182M$229M$2.5B$109M
EBITDAEarnings before interest/tax-$59M$7M$42M$16M
Net IncomeAfter-tax profit-$88M$8M-$171M$5M
Free Cash FlowCash after capex-$42M-$2M$251M$12M
Gross MarginGross profit ÷ Revenue+38.7%+43.0%+65.6%+67.3%
Operating MarginEBIT ÷ Revenue-50.6%+1.4%-7.6%+10.7%
Net MarginNet income ÷ Revenue-48.2%+3.4%-6.8%+4.7%
FCF MarginFCF ÷ Revenue-22.9%-0.9%+10.0%+10.6%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%+29.3%-2.5%-0.2%
EPS Growth (YoY)Latest quarter vs prior year+44.5%+32.1%
OPRX leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

TDOC leads this category, winning 3 of 6 comparable metrics.

At 24.6x trailing earnings, OPRX trades at a 81% valuation discount to TALK's 129.5x P/E. On an enterprise value basis, OPRX's 6.5x EV/EBITDA is more attractive than TALK's 137.8x.

MetricAMWL logoAMWLAmerican Well Cor…TALK logoTALKTalkspace, Inc.TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…
Market CapShares × price$129M$868M$1.3B$124M
Enterprise ValueMkt cap + debt − cash-$48M$830M$1.5B$105M
Trailing P/EPrice ÷ TTM EPS-1.30x129.50x-6.11x24.56x
Forward P/EPrice ÷ next-FY EPS est.38.20x7.04x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple137.77x15.13x6.55x
Price / SalesMarket cap ÷ Revenue0.52x3.79x0.50x1.13x
Price / BookPrice ÷ Book value/share0.50x7.69x0.89x0.98x
Price / FCFMarket cap ÷ FCF4.40x6.62x
TDOC leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

OPRX leads this category, winning 4 of 9 comparable metrics.

TALK delivers a 6.9% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-33 for AMWL. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to TDOC's 0.75x. On the Piotroski fundamental quality scale (0–9), OPRX scores 8/9 vs TDOC's 6/9, reflecting strong financial health.

MetricAMWL logoAMWLAmerican Well Cor…TALK logoTALKTalkspace, Inc.TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…
ROE (TTM)Return on equity-33.5%+6.9%-12.4%+4.2%
ROA (TTM)Return on assets-25.1%+5.9%-5.9%+3.0%
ROICReturn on invested capital-95.1%+3.9%-11.5%+7.1%
ROCEReturn on capital employed-36.6%+2.7%-10.0%+7.6%
Piotroski ScoreFundamental quality 0–96668
Debt / EquityFinancial leverage0.02x0.75x0.04x
Net DebtTotal debt minus cash-$178M-$37M$259M-$19M
Cash & Equiv.Liquid assets$182M$37M$781M$23M
Total DebtShort + long-term debt$5M$0$1.0B$5M
Interest CoverageEBIT ÷ Interest expense-239.18x-8.76x1.26x
OPRX leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TALK leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in TALK five years ago would be worth $5,232 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, TALK leads with a +70.4% total return vs OPRX's -30.1%. The 3-year compound annual growth rate (CAGR) favors TALK at 80.7% vs AMWL's -42.2% — a key indicator of consistent wealth creation.

MetricAMWL logoAMWLAmerican Well Cor…TALK logoTALKTalkspace, Inc.TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…
YTD ReturnYear-to-date+59.8%+47.6%-1.3%-46.6%
1-Year ReturnPast 12 months+14.3%+70.4%+1.5%-30.1%
3-Year ReturnCumulative with dividends-80.7%+490.0%-73.3%-54.4%
5-Year ReturnCumulative with dividends-97.2%-47.7%-95.4%-87.3%
10-Year ReturnCumulative with dividends-98.3%-48.7%-41.1%+110.5%
CAGR (3Y)Annualised 3-year return-42.2%+80.7%-35.6%-23.0%
TALK leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

TALK leads this category, winning 2 of 2 comparable metrics.

TALK is the less volatile stock with a 0.86 beta — it tends to amplify market swings less than OPRX's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.6% from its 52-week high vs OPRX's 29.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAMWL logoAMWLAmerican Well Cor…TALK logoTALKTalkspace, Inc.TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…
Beta (5Y)Sensitivity to S&P 5001.47x0.86x1.91x2.28x
52-Week HighHighest price in past year$9.15$5.20$9.77$22.25
52-Week LowLowest price in past year$3.71$2.22$4.40$5.54
% of 52W HighCurrent price vs 52-week peak+84.7%+99.6%+71.2%+29.8%
RSI (14)Momentum oscillator 0–10067.162.774.146.9
Avg Volume (50D)Average daily shares traded59K4.5M5.5M476K
TALK leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: TALK as "Hold", TDOC as "Hold", OPRX as "Buy". Consensus price targets imply 156.4% upside for OPRX (target: $17) vs 1.4% for TALK (target: $5).

MetricAMWL logoAMWLAmerican Well Cor…TALK logoTALKTalkspace, Inc.TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…
Analyst RatingConsensus buy/hold/sellHoldHoldBuy
Price TargetConsensus 12-month target$5.25$7.58$17.00
# AnalystsCovering analysts104215
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+0.0%+2.0%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

OPRX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TALK leads in 2 (Total Returns, Risk & Volatility).

Best OverallTalkspace, Inc. (TALK)Leads 2 of 6 categories
Loading custom metrics...

AMWL vs TALK vs TDOC vs OPRX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is AMWL or TALK or TDOC or OPRX a better buy right now?

For growth investors, Talkspace, Inc.

(TALK) is the stronger pick with 22. 0% revenue growth year-over-year, versus -2. 0% for American Well Corporation (AMWL). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — AMWL or TALK or TDOC or OPRX?

On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 24.

6x versus Talkspace, Inc. at 129. 5x. On forward P/E, OptimizeRx Corporation is actually cheaper at 7. 0x.

03

Which is the better long-term investment — AMWL or TALK or TDOC or OPRX?

Over the past 5 years, Talkspace, Inc.

(TALK) delivered a total return of -47. 7%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: OPRX returned +110. 5% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — AMWL or TALK or TDOC or OPRX?

By beta (market sensitivity over 5 years), Talkspace, Inc.

(TALK) is the lower-risk stock at 0. 86β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately 165% more volatile than TALK relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — AMWL or TALK or TDOC or OPRX?

By revenue growth (latest reported year), Talkspace, Inc.

(TALK) is pulling ahead at 22. 0% versus -2. 0% for American Well Corporation (AMWL). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to 57. 1% for American Well Corporation. Over a 3-year CAGR, TALK leads at 24. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — AMWL or TALK or TDOC or OPRX?

OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.

7% net margin versus -38. 4% for American Well Corporation — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is AMWL or TALK or TDOC or OPRX more undervalued right now?

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.

0x forward P/E versus 38. 2x for Talkspace, Inc. — 31. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.

08

Which pays a better dividend — AMWL or TALK or TDOC or OPRX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is AMWL or TALK or TDOC or OPRX better for a retirement portfolio?

For long-horizon retirement investors, Talkspace, Inc.

(TALK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TALK: -48. 7%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between AMWL and TALK and TDOC and OPRX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AMWL is a small-cap quality compounder stock; TALK is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

AMWL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 23%
Run This Screen
Stocks Like

TALK

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Gross Margin > 25%
Run This Screen
Stocks Like

TDOC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Stocks Like

OPRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 40%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform AMWL and TALK and TDOC and OPRX on the metrics below

Revenue Growth>
%
(AMWL: -100.0% · TALK: 29.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.